Adis JournalsBrowse
Summary Slide.png (70.2 kB)
Download file

Single-Dose Pharmacokinetics of Ozanimod and Its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study

Download (70.2 kB)
figure
posted on 2020-08-26, 15:47 authored by Jonathan Q. Tran, Peijin Zhang, Atalanta Ghosh, Liangang Liu, Mary Syto, Xiaomin Wang, Maria Palmisano

Article full text


The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.


The above Summary Slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2020.

Funding

Celgene Corporation and Bristol-Myers Squibb Company

History

References

Usage metrics

Read the peer-reviewed publication

Single-Dose Pharmacokinetics of Ozanimod and Its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study
Advances in TherapyAdvances in Therapy

Categories

Keywords

CYP2C8CYP3ADrug interactionGemfibrozilItraconazoleOzanimodPharmacokineticsRifampin

Licence

CC BY-NC 4.0

Exports